ImpediMed Q1 2023 Quarterly Activities Report and Investor Presentation

ImpediMed reports Q1 2023 activities and investor updates following NCCN Guidelines recommendation for BIS in cancer patients at risk of limb lymphoedema. The company achieved significant momentum with private payors and more than doubled its total addressable market in oncology. Key updates highlight the transformative moment for the company's commercialization efforts in the US market.